Wasatch Pharmaceuticals - 500 Beiträge pro Seite

[V51]

hat jemand noch mehr Infos zu Wasatch ? Danke sehr.

Wasatch Pharmaceuticals Ticker: WSCH Page 1 of 10
Complete Financials: December 2001 Exchange OTC
FY END DEC
ISSUE DATA (05/24/02) PER SHARE DATA RATIOS
Price $ 0.00 EPS (TTM) $ -3.61 P/E (TTM) NM
52W High $ 7.00 Div. Rate $ 0.00 Yield 0.00 %
52W Low $ 0.00 Book Value $ -0.17 Price/Book NM
Shrs Out 733.45 Mil Cash $ NM ROE (TTM) NM %
Float 484.10 Mil Rev (TTM) $ 0.03 ROA (TTM) -550.54 %
Mon. Vol 404.49 Mil Curr. Ratio 0.06
Beta -0.68 LT Dbt/Eqty NM
BRIEF: WSCH has developed proprietary technology for the
treatment of various skin disorders and operates two
prototype treatment clinics in Utah. For the FY ended
12/31/01, revenues increased 78% to $53K. Net loss
increased 33% to $3.1M. Revenues reflect benefits
from the marketing efforts for the Internet and Utah
clinics. Net loss reflects increased clinic salaries and
personnel costs and costs related to start-up operations.


Copyright (c) 2002, Market Guide Inc., All rights reserved (more)

Wasatch Pharmaceuticals QUARTERLY SUMMARY Page 2 of 10
HISTORICAL QUARTERLY RESULTS(Thousands of U.S. Dollars)
REVENUE 1998 1999 2000 2001
1st Qtr MAR 21 14 7 23
2nd Qtr JUN 20 12 6 10
3rd Qtr SEP 19 11 7 9
4th Qtr DEC 21 7 10 11
EPS (U.S. Dollars per share)
1st Qtr MAR -0.799 -0.860 -0.767 -1.608
2nd Qtr JUN -0.925 -0.665 -2.100 -1.128
3rd Qtr SEP -0.602 -1.326 -1.110 -0.720
4th Qtr DEC -14.065 -1.011 -5.247 -0.150

Formally Ceron Resources Corp. 9/01, 1-for-50 reverse
stock split; 6/00, 1-for-2 reverse stock split.

DIVIDENDS EMPLOYEES
Last Dividend Decl. $ NA # Employees 12
Last Div Ex-Date NA Sales/Employee (TTM) 4,417
Last Div Pay Date NA Net. Income/Empl.(TTM) NM

Copyright (c) 2002, Market Guide Inc., All rights reserved (more)

Wasatch Pharmaceuticals COMPANY COMPARISON Page 3 of 10
TO THE HEALTH CARE AND S&P 500 AGGREGATES
VALUATION RATIOS: COMPANY INDUSTRY S&P 500
P/E Ratio NM 29.03 29.18
Dividend Yield 0.00 0.04 1.48
Price to Tangible Book -0.01 9.59 8.00
Price to Book NM 3.80 5.25
Price to Free Cash Flow 0.00 22.84 36.26
GROWTH STATISTICS:
3 Yr Rev Growth -13.19 19.43 12.45
3 Yr EPS Growth NM 27.03 11.02
3 Yr Div Growth NM 0.68 9.27
Reinvestment Rate 100.00 98.01 68.85
PROFITABILITY RATIOS:
Net Profit Margin NM 4.84 9.53
Return on Equity NM 13.39 16.43
Interest Coverage -5.35 7.38 8.90
FINANCIAL STRENGTH RATIOS:
Current Ratio 0.06 1.97 1.58
LT Debt to Equity NM 0.80 0.75
Total Debt to Equity NM 0.87 1.11
Copyright (c) 2002, Market Guide Inc., All rights reserved (more)

Wasatch Pharmaceuticals TRADING & PRICE PERFORMANCE Page 4 of 10
INSTITUTIONAL OWNERSHIP INSIDER TRADING (Prev. 6 months)
% Shares Out. Owned NA % Net Insider Trades NA
# of Institutions NA # Buy Transactions NA
Total Shs Held NA Mil # Sell Transactions NA
3 Mo. Net Purch. NA Mil Net Shares Bought NA Mil
3 Mo. Shs Purch. NA Mil # Shares Bought NA Mil
3 Mo. Shs Sold NA Mil # Shares Sold NA Mil

4 Week Price % Change 0.0% 4 Week Rel. Price % Change -0.7%
13 Week Price % Change -95.0% 13 Week Rel. Price % Change -95.0%
26 Week Price % Change -98.9% 26 Week Rel. Price % Change -98.8%
52 Week Price % Change -100.0% 52 Week Rel. Price % Change -100.0%
YTD Week Price % Change -98.8% YTD Week Rel. Price % Change -98.7%


MARKET MAKERS: NITE HILL ALEX PGON SCHB HRZG NATL FLTT LTCO




Copyright (c) 2002, Market Guide Inc., All rights reserved (more)

Wasatch Pharmaceuticals EQUITY, OFFICERS & ADDRESS Page 5 of 10
Common Stock $.001 Par, 4/02, unlimited auth., 733,451,105
issd. Insiders own 14%. 3 others own 74%. 12/29/95, Ceron
Resources Corp. merged with Medisys by issuing 1,777,040
shares and changed name to Wasatch Pharmaceutical, Inc.
Preferred Stock $.001 Par, 1M auth., 49,258 issd.


OFFICERS: Gary V. Heesch, Pres./CEO, David K. Giles, CFO/
Secy. TRANSFER AGENT: Fidelity Transfer Co., Salt Lake
City, UT. Company incorporated 1980 in UT. Direct
inquiries to: Gary V. Heesch, Pres./CEO.

ADDRESS & PHONE NUMBERS
Wasatch Pharmaceuticals
310 East 4500 South
Murray, UT 84107
PHONE: [phone]
FAX: [phone]


Copyright (c) 2002, Market Guide Inc., All rights reserved (more)

Wasatch Pharmaceuticals ANNUAL INCOME STATEMENT Page 6 of 10
(Thousands of U.S. Dollars)
12M 12/31/98 12M 12/31/99 12M 12/31/00 12M 12/31/01
Professional Fees 29 14 9 10
Product Sales 52 30 21 43
Total Revenue 81 44 30 53
Cost of Products 5 3 4 18
Selling/Gen./Admin. 1,187 714 1,792 2,367
Employee Leasing 0 0 0 0
Other Operating 89 131 109 204
Interest 254 358 448 494
Depreciation 5 5 26 35
Advertising 0 2 3 72
Total Expenses 1,540 1,213 2,382 3,190
Operating Income -1,459 -1,169 -2,352 -3,137






Copyright (c) 2002, Market Guide Inc., All rights reserved (more)

Wasatch Pharmaceuticals ANNUAL INCOME STATEMENT Page 7 of 10
(Thousands of U.S. Dollars)
12M 12/31/98 12M 12/31/99 12M 12/31/00 12M 12/31/01
Operating Income -1,459 -1,169 -2,352 -3,137
Income Before Taxes -1,459 -1,169 -2,352 -3,137
Income Taxes 0 0 0 0
Income After Taxes -1,459 -1,169 -2,352 -3,137
Pri/Bas EPS Ex. XOrd -7.042 -6.674 -7.347 -1.710
Pri/Bas EPS In. XOrd -7.042 -6.674 -7.347 -1.710
Primary/Basic Avg Sh 207.18 175.16 320.12 1,834.60
Common Dividends/Shr 0.0000 0.0000 0.0000 0.0000










Copyright (c) 2002, Market Guide Inc., All rights reserved (more)

Wasatch Pharmaceuticals SELECTED INCOME STATEMENT Page 8 of 10
(Thousands of U.S. Dollars)
QUARTERS YEAR TO DATE
3M 12/31/00 3M 12/31/01 12M 12/31/00 12M 12/31/01
Revenue 10 11 30 53
Operating Expenses 1,128 796 2,382 3,190
Operating Income -1,118 -785 -2,352 -3,137
Non-Operating Income 0 0 0 0
Non-Operating Expenses 0 0 0 0
Income Before Taxes -1,118 -785 -2,352 -3,137
Income Taxes 0 0 0 0
Adjustments to Income 0 0 0 0
Inc. for Primary EPS -1,118 -785 -2,352 -3,137
Pri/Bas EPS Ex. XOrd -5.247 -0.150 -9.227 -3.606
Disc Opns + Xord Items 0 0 0 0
Pri/Bas EPS In. XOrd -5.247 -0.150 -9.227 -3.606
Primary/Basic Avg Sh 213.06 5,233.31 310.41 1,834.60
Dilutd EPS Excl XOrd -5.247 -0.150 -9.227 -3.606
Dilutd EPS Incl XOrd -5.247 -0.150 -9.227 -3.606
Common Dividends/Shr 0.000 0.000 0.000 0.000

Copyright (c) 2002, Market Guide Inc., All rights reserved (more)

Wasatch Pharmaceuticals SELECTED BALANCE SHEET Page 9 of 10
(Thousands of U.S. Dollars)
YEAR ENDING QUARTER ENDING
12/31/00 12/31/01 12/31/00 12/31/01
Cash & ST Investments 0 0 0 0
Receivables 2 5 2 5
Total Current Assets 190 349 190 349
LT Investments 0 0 0 0
Fixed Assets 144 181 144 181
Total Assets 416 594 416 594
Accounts Payable 518 784 518 784
ST Debt & Curr LTD 2,084 2,674 2,084 2,674
Total Current Liab. 4,227 5,913 4,227 5,913
LT Debt & Cap Leases 0 0 0 0
Total Liabilities 4,227 5,913 4,227 5,913
Preferred Stock 0 0 0 0
Common/Paid In Capital 3,938 6,156 3,938 6,156
Retained Earnings -7,746 -10,885 -7,746 -10,885
Total Equity -3,809 -5,319 -3,809 -5,319
Shares Outstanding 548 31,761 548 31,761

Copyright (c) 2002, Market Guide Inc., All rights reserved (more)

Wasatch Pharmaceuticals SELECTED STMT OF CASH FLOWS Page 10 of 10
INDIRECT METHOD (Thousands of U.S. Dollars)
ANNUAL YEAR TO DATE
12M 12/31/00 12M 12/31/01 12M 12/31/00 12M 12/31/01
Net Income -2,353 -3,139 -2,353 -3,139
Depreciation & Amort. 26 77 26 77
Non Cash Items 613 462 613 462
Total Operating CF -1,170 -1,662 -1,170 -1,662
Capital Expenditures -153 -93 -153 -93
Total Investing CF -225 -96 -225 -96
Dividends Paid 0 0 0 0
Sale (Purch.) of Stock 1,144 1,054 1,144 1,054
Net Borrowings 354 771 354 771
Total Financing CF 1,384 1,757 1,384 1,757
Exchange Rate Effect 0 0 0 0
Net Change In Cash -10 0 -10 0
Oper CF-Cap Exp-Div Pd -1,323 -1,755 -1,323 -1,755




Copyright (c) 2002, Market Guide Inc., All rights reserved

[V51]

http://www.wasatchpharm.com/corporate.html

hab noch das.

Jemand mehr Infos oder gar ne Meinung pro / kontra eines Zocks ?

[cariocca]

V51...

Bin auch mit 2`000`000 Shares in WSCH investiert.

Warten und Beten


Roger

[V51]

also keiner hat da was ?